A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT07217015. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.
Study identification
- NCT ID
- NCT07217015
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2025 (Actual)
- Primary completion
- Jun 2027 (Estimated)
- Completion
- Jun 2028 (Estimated)
- Last update posted
- Oct 6, 2026
2025 – 2028
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kymera Investigative Site | Birmingham | Alabama | 35244 | — |
| Kymera Investigative Site | North Little Rock | Arkansas | 72117 | — |
| Kymera Investigative Site | Los Angeles | California | 90025 | — |
| Kymera Investigative Site | Los Angeles | California | 90045 | — |
| Kymera Investigative Site | Delray Beach | Florida | 33484 | — |
| Kymera Investigative Site | Jacksonville | Florida | 32256 | — |
| Kymera Investigative Site | Miami | Florida | 33137 | — |
| Kymera Investigative Site | Miami | Florida | 33162 | — |
| Kymera Investigative Site | Miramar | Florida | 33027 | — |
| Kymera Investigative Site | Normal | Illinois | 61761 | — |
| Kymera Investigative Site | Ann Arbor | Michigan | 48103 | — |
| Kymera Investigative Site | Detroit | Michigan | 48202 | — |
| Kymera Investigative Site | The Bronx | New York | 10455 | — |
| Kymera Investigative Site | Fargo | North Dakota | 58103 | — |
| Kymera Investigative Site | Portland | Oregon | 97201 | — |
| Kymera Investigative Site | Portland | Oregon | 97239 | — |
| Kymera Investigative Site | Philadelphia | Pennsylvania | 19103 | — |
| Kymera Investigative Site | San Antonio | Texas | 78213 | — |
| Kymera Investigative Site | San Antonio | Texas | 78218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07217015, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07217015 live on ClinicalTrials.gov.